DRUG DISCOVERY
RevolKa is developing its own drug discovery pipeline targeting inherited metabolic diseases using proprietary designs powered by aiProtein®.
As of January 31, 2025 | |||||||
Project | Indication | Partner | Discovery/Preclinical | Clinical | |||
Lead Discovery |
Preclinical | Ph1 | Ph2 | Ph3 | |||
RKD001 | Rare Disease |
![]() |
![]() |
||||
RKD002 | Rare Disease |
![]() |
![]() |
||||
RKD003 | Rare Disease |
![]() |
![]() |
||||
RKD004 | Rare Disease |
Undisclosed | ![]() |